
|Articles|September 15, 2002
Macugen research: Enrollment ends early in trials for wet AMD drug
New York-Eyetech Pharmaceuticals Inc. has completed enrollment in two phase III trials of Macugen, its treatment for wet age-related macular degeneration (AMD), and has received $54.2 million from investors for further development of the drug.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves NDA labeling supplement allowing re-administration of iDose TR
2
Opus Genetics launches phase 1/2 MERTK gene therapy trial
3
Dr. Mali’s top 5 predictions in ophthalmology for 2026
4
Cloudbreak Pharma completes FDA end-of-phase-2 meeting for CBT-004 in pinguecula
5



























